Related Experiment Video
Updated: May 12, 2026
12:04
The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
Published on: November 1, 2015
Epratuzumab for systemic lupus erythematosus.
1Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. dwallace@ucla.edu
Lupus
|April 5, 2013
Summary
Epratuzumab is a humanized monoclonal antibody targeting CD22 being investigated for autoimmune disorders like systemic lupus erythematosus (SLE). It shows anti-inflammatory activity and potential as a treatment for these conditions.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Epratuzumab is a humanized monoclonal antibody that targets the CD22 antigen.
- CD22 is expressed on B cells, which play a role in autoimmune diseases.
Purpose of the Study:
- To review the mechanism of action of Epratuzumab.
- To summarize completed and ongoing clinical trials of Epratuzumab in systemic lupus erythematosus (SLE) and other rheumatic and hematologic conditions.
- To assess the anti-inflammatory potential of Epratuzumab in autoimmune disorders.
Main Methods:
- Review of preclinical data and clinical trial results.
- Analysis of Epratuzumab's interaction with CD22 and its downstream effects.
- Evaluation of clinical efficacy and safety data from SLE studies.
Main Results:
- Epratuzumab demonstrates a clear anti-inflammatory effect.
- Clinical trials have provided data on its use in various autoimmune conditions.
- Ongoing studies are further evaluating its therapeutic potential.
Conclusions:
- Epratuzumab is a promising therapeutic agent for autoimmune diseases.
- Its anti-inflammatory properties suggest a role in managing conditions like SLE.
- Further research and clinical trials are warranted to establish its full therapeutic value.